BACKGROUND AND OBJECTIVES: Gastric and intestinal mucin phenotype cell markers are widely expressed in gastric carcinoma cells, irrespective of their tumor histological type. In the present study, we tried to reveal the clinicopathological significance of mucin phenotype in human gastric carcinomas. Moreover, we investigated the clinical significance of RUNX3 in association with mucin phenotype. METHODS: The mucin expression of MUC5AC, MUC6, MUC2, and CD10 was evaluated in 97 gastric carcinomas by immunohistochemistry. Tumors were classified into gastric (G), gastric and intestinal mixed (GI), intestinal (I), and null (N) phenotype according to combination of mucin expression. RESULTS: The rate of G, GI, I, and N phenotype was 40.0%, 38.1%, 10.3%, and 19.6%, respectively. Mucin phenotype was also significantly correlated with several clinicopathological findings. Patients with I phenotype had a significantly poorer prognosis than those with any other phenotypes. They also had a higher rate of postoperative liver metastasis. Multivariate analysis revealed that mucin phenotype was a significant independent prognostic factor. We suggested that Loss of RUNX3 expression might correlate with intestinal phenotype and postoperative outcome. CONCLUSIONS: Mucin phenotype has a significant prognostic value and may be a useful marker for the treatment of human gastric carcinoma.
BACKGROUND AND OBJECTIVES: Gastric and intestinal mucin phenotype cell markers are widely expressed in gastric carcinoma cells, irrespective of their tumor histological type. In the present study, we tried to reveal the clinicopathological significance of mucin phenotype in humangastric carcinomas. Moreover, we investigated the clinical significance of RUNX3 in association with mucin phenotype. METHODS: The mucin expression of MUC5AC, MUC6, MUC2, and CD10 was evaluated in 97 gastric carcinomas by immunohistochemistry. Tumors were classified into gastric (G), gastric and intestinal mixed (GI), intestinal (I), and null (N) phenotype according to combination of mucin expression. RESULTS: The rate of G, GI, I, and N phenotype was 40.0%, 38.1%, 10.3%, and 19.6%, respectively. Mucin phenotype was also significantly correlated with several clinicopathological findings. Patients with I phenotype had a significantly poorer prognosis than those with any other phenotypes. They also had a higher rate of postoperative liver metastasis. Multivariate analysis revealed that mucin phenotype was a significant independent prognostic factor. We suggested that Loss of RUNX3 expression might correlate with intestinal phenotype and postoperative outcome. CONCLUSIONS:Mucin phenotype has a significant prognostic value and may be a useful marker for the treatment of humangastric carcinoma.
Authors: Christopher M Evans; Tasha E Fingerlin; Marvin I Schwarz; David Lynch; Jonathan Kurche; Laura Warg; Ivana V Yang; David A Schwartz Journal: Physiol Rev Date: 2016-10 Impact factor: 37.312
Authors: Junghee Lim; Tam Duong; Nga Do; Phuong Do; Jaetaek Kim; Hyuncheol Kim; Wael El-Rifai; H Earl Ruley; Daewoong Jo Journal: Clin Cancer Res Date: 2012-12-10 Impact factor: 12.531
Authors: Jung-Soo Pyo; Young San Ko; Guhyun Kang; Dong-Hoon Kim; Woo Ho Kim; Byung Lan Lee; Jin Hee Sohn Journal: J Cancer Res Clin Oncol Date: 2014-12-05 Impact factor: 4.553